Second line chemotherapy with irinotecan (CPT-11) and mitomycin-C (MMC) in patients with advanced/metastatic colorectal (CC) and gastric cancer (GC): A phase II trial.

被引：0
|
作者：
Papamichael, D
Bamias, A
Ioannides, G
Syrigos, K
Demosthenous, C
Pavlidis, N
机构：
[1] Univ Athens, Sotiria Hosp, Dept Med 3, Athens, Greece
[2] Ioannina Univ Hosp, Ioannina, Greece
[3] BO Cyprus Oncol Ctr, Nicosia, Cyprus
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
250
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [31] Irinotecan/mitomycin C (IRI/MMC) combination as second-line chemotherapy in patients with metastaic gastric carcinoma: A phase II study.
    Narimanov, M.
    Kanagavel, D.
    Tryakin, A.
    Tjulandin, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] A phase I trial of CPT-11 and S-1 combination chemotherapy in patients with metastatic colorectal cancer
    Yamaguchi, Yoshiyuki
    Minami, Kazuhito
    Kawabuchi, Yoshiharu
    Ohshita, Akiko
    Hironaka, Katsuji
    HEPATO-GASTROENTEROLOGY, 2008, 55 (82-83) : 407 - 411
  • [33] A phase II trial of CPT-11 in patients (pts) with advanced gastric carcinoma (AGC)
    Kohne, C
    Thusspatience, P
    Catane, R
    Klein
    Peretz, T
    Ducreux, NM
    Wilke, H
    Jacques, C
    ANNALS OF ONCOLOGY, 1998, 9 : 46 - 46
  • [34] Phase II study of CPT-11 plus CDDP in patients with metastatic gastric cancer
    Narahara, H
    Imamura, H
    Ikeda, M
    Kobayashi, K
    Fujitani, K
    Kato, M
    Iwamoto, H
    Takabayashi, A
    Tsukuma, H
    Tsujinaka, T
    Furukawa, H
    Taguchi, T
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 438 - 438
  • [35] A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
    Rothenberg, ML
    Cox, JV
    DeVore, RF
    Hainworth, JD
    Pazdur, R
    Rivkin, SE
    Macdonald, JS
    Geyer, CE
    Sandbach, J
    Wolf, SL
    Mohrland, JS
    Elfring, GL
    Miller, LL
    Von Hoff, DD
    CANCER, 1999, 85 (04) : 786 - 795
  • [36] Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial
    Souglakos, J
    Syrigos, K
    Potamianou, A
    Polyzos, A
    Boukovinas, I
    Androulakis, N
    Kouroussis, C
    Vardakis, N
    Christophilakis, C
    Kotsakis, A
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2004, 15 (08) : 1204 - 1209
  • [37] Randomized phase II study of CPT-11 plus mitomycin C versus oxaliplatin plus mitomycin C in previously treated patients with advanced colorectal cancer (ACC)
    Ulrich-Pur, H
    Brugger, S
    Kornek, GV
    Fiebiger, W
    Haider, K
    Kwasny, W
    Depisch, D
    Kovats, E
    Lang, F
    Scheithauer, W
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S72 - S73
  • [38] Weekly irinotecan (CPT-11) as second-line treatment in patients with 5-FU refractory metastatic colorectal cancer.
    Beni, A
    Zidan, J
    Epelbaum, R
    Sikorsky, N
    Michaeli, B
    Skigin, R
    Kuten, A
    ANNALS OF ONCOLOGY, 2000, 11 : 55 - 55
  • [39] Phase II study of irinotecan (CPT-11) alone in patients (pts) with metastatic pancreatic cancer.
    Funakoshi, A
    Okusaka, T
    Ishii, H
    Sawaki, A
    Ohkawa, S
    Ishikawa, O
    Saitoh, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 338S - 338S
  • [40] Biweekly administration in two diferent dose levels of irinotecan (CPT-11), in patients with advanced colorectal cancer (CRC), according to toxicity prognostic factors.: A phase II trial.
    Saigí, E
    Salut, A
    Campos, JM
    Manzano, H
    Batiste-Alentom, E
    Arcusa, A
    Losa, F
    Vélez, E
    Guasch, I
    Gallego, O
    ANNALS OF ONCOLOGY, 2000, 11 : 44 - 44
12345